An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Orexo announced it finished a first preclinical study of an oral semaglutide tablet. In plain terms: the company tested a pill form of semaglutide in laboratory research that is not yet in people, and they reported early results. This is an early step on the long path toward a new way to take a medicine that is usually given by injection. Semaglutide is the active ingredient in drugs you may have heard of, like Ozempic and Wegovy. It’s a man-made version of a natural hormone your gut releases after you eat. That hormone tells your brain you’re full and slows down how fast your stomach empties, so semaglutide helps reduce appetite and can lead to weight loss and better blood-sugar control. Right now most semaglutide products are given by injection under the skin on a weekly schedule. The study here was preclinical, which means it was done before human trials — typically in lab models such as cells or animals. The company says they completed that first step for a tablet form of semaglutide. The snippet doesn’t give details about how many animals were used, how big the effects were, or whether absorption and dosing matched injected versions. So we only know the milestone was reached, not the size or reliability of any benefit. Preclinical success is necessary but far from proof that a drug will work or be safe in people. Why this matters: an effective oral semaglutide tablet would be a big convenience change for people who need the drug for diabetes or weight management and prefer a pill to an injection. Pills are easier to take for many people and could increase how many stick with treatment. It could also open the market to more patients and simplify dosing in everyday life if later human trials confirm the pill works as well as injections. There are important caveats and risks. Preclinical results often don’t translate to humans; many drugs that look promising in animals fail in safety or effectiveness during clinical trials. Oral delivery of peptide drugs (peptides are small proteins) is technically challenging because stomach acid and digestion usually break them down. Side effects known with injected semaglutide—nausea, vomiting, and rare but serious effects on the pancreas or gallbladder—would still need careful study for an oral form. The announcement doesn’t mean a pill is approved or available; it’s an early research milestone, and further human trials and regulatory review would be required. Bottom line: Orexo reports an early lab-stage win toward making semaglutide as a pill, but it’s a small step — useful news, but not proof yet that an oral version will be safe, effective, or available to patients.
Source: TradingView